Louise Willoughby

Louise Willoughby started their work experience as a Clinical Sales Specialist at Praxair Distribution, Inc. in November 2017, and they worked in this role until April 2019. Following that, they worked as an Account Executive at Nova Biomedical from July 2019 to April 2022. Currently, they are working as a Business Development Manager for the Central United States at Immunexpress Inc., starting from March 2022. In their current role, they are responsible for promoting a new molecular test for sepsis called SeptiCyte Rapid, which quantitatively differentiates Systemic Inflammatory Response Syndrome from Sepsis.

Louise Willoughby earned a Master of Business Administration (MBA) degree from Texas Wesleyan University, which they completed between 1998 and 2000. In addition to their formal education, they obtained a certification in "Optimize Your Resume for Applicant Tracking Systems" from LinkedIn in January 2022.